[Skip to Navigation]
March 11, 2020

Disappointing Early Results From Opioid Prescribing Limits for Acute Pain

Author Affiliations
  • 1Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor
  • 2Michigan Opioid Prescribing Engagement Network, Ann Arbor
  • 3Division of Pain Medicine, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor
JAMA Surg. 2020;155(5):375-376. doi:10.1001/jamasurg.2019.5891

Between 2016 and 2019, the United States experienced a rapid proliferation of limits restricting the duration or number of doses in opioid prescriptions for acute pain.1 As of October 2019, such limits have been enacted by 34 states; large payers, such as Medicare, several state Medicaid programs, Aetna, and UnitedHealth; pharmacy chains, such as Sam’s Club/Walmart; and major pharmacy benefit managers, such as CVS CareMark, ExpressScripts, and OptumRx, which collectively manage drug benefits for 180 million Americans.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words